Unicorn Biotechnologies is a technology company.
Unicorn Biotechnologies has raised $3.0M across 1 funding round.
Unicorn Biotechnologies has raised $3.0M in total across 1 funding round.
Unicorn Biotechnologies is a biotechnology company developing automated machines, consumables, and services to streamline and industrialize cell culture workflows, particularly for mammalian cells like iPSCs.[1][2][5] It serves life sciences researchers, biotech firms in drug discovery, regenerative medicine, cell & gene therapies, and cultivated meat by solving manual, labor-intensive processes that hinder R&D speed and scaling, reducing labor by 80%+, variability by 50%+, and costs by 25-50% through AI-driven control, modular systems, and seamless bench-to-commercial scalability.[1][2][3] Growth momentum includes partnerships with accelerators like HAX and SOSV, a product pipeline featuring the Emmet system and GMP-ready versions, plus revenue streams from technology licensing and "Cell-manufacturing-as-a-Service."[2][3][4]
Founded on December 9, 2020, in Sheffield, England, Unicorn Biotechnologies was co-founded by Dr. Adam Glen, a PhD in cancer research with experience in academia, GE Healthcare, and biotech startups, specializing in stem cell biology, tissue engineering, and hardware for life sciences.[1][6] The idea emerged from Glen's frustration with inefficient manual cell culture—unchanged since the 1950s—driving a mission to automate workflows for basic research, drug discovery, and scalable manufacturing in the bioeconomy.[1][2] Early traction came via accelerators HAX and SOSV, R&D product development like Emmet for stem cell expansion, and contract services in cellular/molecular biology, positioning it as a tech integrator for self-driving labs and bioproduction.[2][3][4]
Unicorn rides the century of biology wave in a trillion-dollar bioeconomy, addressing trillion-scale markets in longevity, cell/gene therapies, regenerative medicine, and cultivated meat via industrialized mammalian cell production.[2][3] Timing aligns with post-1950s stagnation in cell culture, amplified by needs for rapid scaling amid biological threats, domestic bioproduction resurgence (e.g., US/allied automated bio-factories), and trends like autonomous foundries for vaccines.[4] Market forces favoring it include high failure rates/costs of manual methods (hundreds of thousands per therapy) and demand for robust, cost-effective scaling; it influences the ecosystem by enabling faster R&D, removing lab-to-clinic barriers, and powering cellular agriculture revolutions.[1][2][4]
Unicorn Biotechnologies is poised to become as ubiquitous as PCR machines in biotech labs, expanding Emmet deployments and GMP systems while scaling contract services and as-a-service models amid bioeconomy acceleration.[1][2] Trends like automated bioproduction foundries, self-driving labs, and resilient supply chains for threats (e.g., high-quality vaccines) will shape its path, with AI/hardware integration driving domestic manufacturing rebuilds.[4] Its influence may evolve into a core enabler for scalable therapies and novel proteins, amplifying R&D velocity from Sheffield to global bio-factories—transforming artisanal cell work into industrial power.[2][3]
Unicorn Biotechnologies has raised $3.0M in total across 1 funding round.
Unicorn Biotechnologies's investors include Acequia Capital, Almaz Capital, Batalion Capital, Curiosity VC, Dorm Room Fund, Karma Ventures, Kompas VC, SOSV, Verve Ventures, Jim Williams, Logan Lorenz, Peter Rojas.
Unicorn Biotechnologies has raised $3.0M across 1 funding round. Most recently, it raised $3.0M Seed in April 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Apr 1, 2022 | $3.0M Seed | Acequia Capital, Almaz Capital, Batalion Capital, Curiosity VC, Dorm Room Fund, Karma Ventures, Kompas VC, SOSV, Verve Ventures, Jim Williams, Logan Lorenz, Peter Rojas |